Home › Prostate Cancer › NCT04472338
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
PATROL: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease
Who can join
Ages 40 and older · Men · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * People with prostates ≥40 years of age * Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk. Exclusion Criteria: * Prior diagnosis of prostate cancer * Medical contraindication to any of the study procedures (e.g., prostate biopsy) * For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy) * Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk * Unable to provide written informed consent * Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.
About the study
This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.
What is being tested
- Biospecimen Collection (procedure)
- Laboratory Biomarker Analysis (other)
- Quality-of-Life Assessment (other)
- Questionnaire Administration (other)
Sponsor: University of Washington · Participants: 450 · Started: May 21, 2020
Contact the study team
- Study Team Coordinator · Phone: 206-210-4040
Official record on ClinicalTrials.gov — NCT04472338
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.